Status:
COMPLETED
US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector
Lead Sponsor:
Bayer
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
In this study researchers want to learn more about the medication usage behavior among multiple sclerosis (MS) patients treated with BETASERON using the myBETAapp. Multiple sclerosis (MS) is a disease...
Eligibility Criteria
Inclusion
- Aged ≥18 years
- Treated with BETASERON using the BETACONNECT autoinjector
- Registered with myBETAapp
- Provided electronic informed consent
Exclusion
- \- There are no exclusion criteria for participation in this study
Key Trial Info
Start Date :
November 24 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 11 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04356339
Start Date
November 24 2020
End Date
November 11 2021
Last Update
July 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
myBETAapp
Whippany, New Jersey, United States, 07981